Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Related News

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Analysts' corner

Ranbaxy Laboratories & Havells India

After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

image

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Recommended for you

Quick Links

Market News

Nickel rises by 0.1% on Asian cues

Traders strengthened positions amid a firming Asian cues

Oil prices rise further in Asia

Expectations of a decline in US crude inventories and robust economic data from the eurozone helped prices

Markets remain rangebound; HUL up over 2%, Hindalco dips 1%

Investors are optimistic about a possible solution between Greece and its international creditors to avert a debt crisis

Pharma shares in focus; Aurobindo Pharma hits new high

JB Chemicals, Alembic Pharma, Aurobindo Pharma, Ipca Laboratories and Dishman Pharma were up 3%-11% each.

Infinite Computer gains on board approval for share buyback proposal

The stock spurted 5% at Rs 171 after the board approved the buyback of shares at a maximum price of Rs 220 per share from the open market ...

 

Back to Top